Oxford Spin-Out Just Raised $300M: What It Means for Biotech

Jan de Vries · 2026-10-16

You know that feeling when a small company suddenly lands a massive check? That's exactly what happened to OMass Therapeutics, a UK biotech spun out of Oxford. They just closed an oversubscribed Series C round of €275 million—that's about $300 million. And it's not just the size that's impressive; it's who's writing the checks. ### Who's putting money in? The round was co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings. Existing investors like Syncona, Oxford Science Enterprises, GV, and Sanofi Ventures also joined in. That kind of backing tells you something: people believe in what OMass is building. Ros Deegan, the CEO, put it this way: "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow." In plain English: they've got promising drugs and now they have the cash to push them through trials. ### What's the big deal about OMass? Founded in 2016, OMass is a spin-out from Professor Dame Carol Robinson's lab at Oxford. They're using native mass spectrometry—a fancy way to study proteins in their natural environment—to develop small molecule drugs against targets that have been notoriously hard to drug. Their platform, called OdyssION, combines mass spec, biochemistry, and custom chemistry to look at drug targets in their native ecosystems. Think of it like studying animals in the wild instead of in a zoo—you get a more accurate picture of how they really behave. ### Where's the money going? The main focus is OMS1620, a potential best-in-class drug for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It's heading into Phase 2 trials. If it works, it could be a game-changer for patients with these rare endocrine disorders. But OMass isn't the only European biotech raking in cash this year. Here's a quick rundown of other notable rounds in 2026: - **Bionyra Pharma** (France): €143 million ($156 million) for inflammatory diseases - **Breye Therapeutics** (Denmark): €67.5 million ($74 million) for oral small molecules - **STORM Therapeutics** (UK): €47.5 million ($52 million) - **Microbiotica** (UK): €42 million ($46 million) - **Mironid** (UK): €39.9 million ($43.5 million) - **Alchemab Therapeutics** (UK): €29.3 million ($32 million) - **Laigo Bio** (Netherlands): €5.5 million ($6 million) Add those up and you get roughly €374.7 million ($409 million) in new financing—and that's before OMass's round. With OMass included, the total jumps to about €649.7 million ($709 million). That's a lot of confidence in European therapeutics. ### Why this matters for the US audience If you're in the US biotech scene, you might be wondering why you should care about a UK company. Well, for starters, the drugs they're developing could eventually reach American patients. And the investors? Many are global players like Bain Capital and Novo Holdings, who have deep ties to the US market. Plus, it's a sign that the European biotech ecosystem is maturing. More money flowing into early-stage research means more potential partnerships and acquisitions down the line. So keep an eye on OMass—they might just be the next big thing in endocrine and immunology treatments. ### The bottom line OMass Therapeutics just raised a boatload of cash to push its lead drug through trials. With a proprietary platform and a team that's already delivering, they're one to watch. And if the recent funding frenzy in Europe is any indication, we'll be hearing a lot more about biotech breakthroughs from across the pond. As Evan Greif from Bain Capital said, "We see meaningful potential for OMS1620 to improve the treatment for patients with CAH." That's the kind of optimism that drives innovation—and investors.